Eir Ventures invests in Hoba Therapeutics

Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development  for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a unique MoA targeting the peripheral nervous system to reverse neuropathic pain and thus targeting the underlying cause of the disease. HB-097 is a restorative treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.

Read the full Press Release here